Pharmacology and pharmacokinetics of antibody-drug conjugates, where do we stand?
Cancer Treatment Reviews · 2025-04 · 135 · 102922
DOI: 10.1016/j.ctrv.2025.102922 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Treatment Reviews, 2025-04. Verfasst von Arthur Géraud und 20 weiteren Autor:innen. Beteiligte Einrichtung: Aix-Marseille Univ, CNRS, INSERM, Institut Paoli-Calmettes, Department of Medical Oncology, CRCM, Marseille, France; COMPO Team, Centre de Recherche …. Hauptthemen laut MEDLINE: Immunoconjugates, Neoplasms. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 112 Literaturangaben.
Abstract (Originalsprache)
Antibody-drug conjugates (ADCs) are a rising therapeutic class in oncology and hematology, with eleven drugs approved by the US Food and Drug Administration as of January 2025. These "magic bullets" have a complex structure, including a monoclonal antibody, a linker, attachment sites, and a payload usually disrupting microtubules, targeting DNA, or inhibiting topoisomerase 1. By targeting specific tumor antigens, they are expected to be exquisitely effective in releasing "supertoxic" payloads inside tumor cells after intracellular trafficking. Additionally, they may exert a bystander effect, wherein the released payloads act on neighboring cells, amplifying their therapeutic impact regardless of target expression. ADCs have been game-changing drugs to treat tumors with once dismal prognoses or with previously considered unactionable targets, such as HER2-low or triple-negative breast cancer. To what extent there is room for personalized medicine to improve the toxicity/efficacy ratio remains unknown. However, there are inherent issues related to the complexity of the pharmacokinetics of ADCs and their assessments: efficacy or toxicity may be influenced by the clearance of the intact ADC, the circulating payload, or the payload-linker complex. Deciphering these multifaceted exposure-outcomes relationships for both efficacy and safety endpoints, is critical for advancing precision medicine and enabling personalized dosing strategies. To improve future developments and broaden their therapeutic scope, several strategies can be developed, including developing adequate combinations with other treatment classes (cytotoxic agents, immune-checkpoint inhibitors, oral molecular-targeted therapies). In this review, we will discuss the PK/PD aspects of ADCs and their dosing to improve their use in current and future indications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Aix-Marseille Univ, CNRS, INSERM, Institut Paoli-Calmettes, Department of Medical Oncology, CRCM, Marseille, France; COMPO Team, Centre de Recherche en Cancérologie de Marseille (CRCM), Inserm U1068, Aix Marseille Unive…
- Department of Medical Oncology, Pitié-Salpêtrière, Assistance Publique - Hôpitaux de Paris (AP-HP), 75013 Paris, France; Sorbonne Université, Institut National de la Santé et de la Recherche Médicale (INSERM), Assistanc…
- Aix-Marseille Univ, CNRS, INSERM, Institut Paoli-Calmettes, Department of Medical Oncology, CRCM, Marseille, France.
- Department of Hematology, Institut Paoli-Calmettes, CRCM, Aix-Marseille University,13009 Marseille, France.
- COMPO Team, Centre de Recherche en Cancérologie de Marseille (CRCM), Inserm U1068, Aix Marseille University, 13009 Marseille, France; Department of Multidisciplinary Oncology and Therapeutic Innovations, Assistance Publ…
- Department of Medical Oncology, Pitié-Salpêtrière, Assistance Publique - Hôpitaux de Paris (AP-HP), 75013 Paris, France.
Zitieren
APA
Géraud, A., Gougis, P., de Nonneville, A., Beaufils, M., Bertucci, F., Billon, E., Brisou, G., Gravis, G., Greillier, L., Guerin, M., Mezni, E., Mitry, E., Noel, R., Pignon, J., Sabatier, R., Seguin, L., Spano, J. P., Vicier, C., Viret, F., …, & Ciccolini, J. (2025). Pharmacology and pharmacokinetics of antibody-drug conjugates, where do we stand?. Cancer Treatment Reviews, 135, 102922. https://doi.org/10.1016/j.ctrv.2025.102922
Vancouver
Géraud A, Gougis P, de Nonneville A, Beaufils M, Bertucci F, Billon E, et al. Pharmacology and pharmacokinetics of antibody-drug conjugates, where do we stand?. Cancer Treatment Reviews. 2025;135:102922. doi:10.1016/j.ctrv.2025.102922
BibTeX
@article{Graud2025,
author = {Géraud, Arthur and Gougis, Paul and de Nonneville, Alexandre and Beaufils, Mathilde and Bertucci, François and Billon, Emilien and Brisou, Gabriel and Gravis, Gwenaelle and Greillier, Laurent and Guerin, Mathilde and Mezni, Essia and Mitry, Emmanuel and Noel, Robin and Pignon, Joséphine and Sabatier, Renaud and Seguin, Lorène and Spano, Jean-Philippe and Vicier, Cécile and Viret, Frederic and Goncalves, Anthony and Ciccolini, Joseph},
title = {Pharmacology and pharmacokinetics of antibody-drug conjugates, where do we stand?},
journal = {Cancer Treatment Reviews},
year = {2025},
volume = {135},
pages = {102922},
doi = {10.1016/j.ctrv.2025.102922}
}
EUVIMED